Rodman & Renshaw Starts Eyegate Pharmaceuticals (EYEG) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Eyegate (EYEG) Surges on New 'Buy' Rating
February 1, 2016 9:49 AM ESTEyegate Pharmaceuticals (NASDAQ: EYEG) is surging 66% in early trade after Rodman & Renshaw initiated coverage on with a Buy rating and a price target of $10.00.
... More